ArticleACS central science2022
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with
Erratum issuedAbstract read
In one paragraph
Article in ACS central science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens.ACS infectious diseases · 2026Article
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Random Forest Modeling to Predict Small Molecule Accumulation in Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Computationally Generated Plant-Derived Berberine-Based Hybrid Compounds as Potential Dual Binders toInternational journal of molecular sciences · 2026Article
- Fatty acid biosynthesis inhibitors fabimycin and triclosan trigger distinct resistance mutations in FabI and potently kill Gram-negative pathogens.bioRxiv : the preprint server for biology · 2026Article
- Rediscovering Diazaborines: Synthesis and Bioactivity Profiling of Boron-Containing FabI Inhibitors against Gram-Negative Bacteria.Journal of medicinal chemistry · 2026Article
- Designing AI-generated antimicrobials for targeting bacterial microdomains.Scientific reports · 2025Article
- Novel antimicrobial peptides and peptide-microbiome crosstalk in Appalachian salamander skin.NPJ biofilms and microbiomes · 2025Article
- Development of Pyrimido Pyridazine Analogs through Increased Whole Cell Target Engagement of the Dihydropteroate Synthase Pterin Binding Site in Gram-Negative Bacteria.ACS infectious diseases · 2025Article
- Structure-Activity Relationships and Design of Focused Libraries Tailored for Staphylococcus Aureus Inhibition.Molecular informatics · 2025Article
- Synthesis of Urea-Containing Derivatives and their Application as Potential Anti-Methicillin-Resistant Staphylococcus Aureus Agents.ChemMedChem · 2025Article
- The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo.Nature communications · 2025Article
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Augmentation of Antimicrobial Activity of Spiniferin by Introducing an Arginine Residue Toward Its Amino Terminus: A Possible Role of Cation-π Interaction.ACS bio & med chem Au · 2025Article
- Positive Charge in an Antimalarial Compound Unlocks Broad-Spectrum Antibacterial Activity.JACS Au · 2025Article
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Development of CGS-15943 Adjunctives for the Disruption of Plasmid Maintenance in Multidrug ResistantACS infectious diseases · 2025Article
- HNature communications · 2024Article
- Design and synthesis of a library of C8-substituted sulfamidoadenosines to probe bacterial permeability.Bioorganic & medicinal chemistry letters · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Erica N ParkerDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID https://orcid.org/0000-0001-5982-0458
Brett N CainDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Behnoush HajianBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Rebecca J UlrichDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID https://orcid.org/0000-0001-6013-6565
Emily J GeddesDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Sulyman BarkhoBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Hyang Yeon LeeDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
John D WilliamsWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Malik RaynorWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Diana CaridhaWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Angela ZainoBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Mrinal ShekharBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Kristen A MuñozDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Kara M RzasaBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Emily R TempleBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Diana HuntBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Xiannu JinWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Chau VuongWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Kristina PannoneWalter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States.
Aya M KellyDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Michael P MulliganDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Katie K LeeBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Gee W LauDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID https://orcid.org/0000-0002-7962-3950
Deborah T HungBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.ORCID https://orcid.org/0000-0003-4262-0673
Paul J HergenrotherDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID https://orcid.org/0000-0001-9018-3581
Funding
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum AntibioticsR01AI136773 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HERGENROTHER, PAUL · 2018 to 2022
$6.0MNIAID NIH HHS R01 AI136773
Abstract
Genomic studies and experiments with permeability-deficient strains have revealed a variety of biological targets that can be engaged to kill Gram-negative bacteria. However, the formidable outer membrane and promiscuous efflux pumps of these pathogens prevent many candidate antibiotics from reaching these targets. One such promising target is the enzyme FabI, which catalyzes the rate-determining step in bacterial fatty acid biosynthesis. Notably, FabI inhibitors have advanced to clinical trials for
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.